The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1717
December 9, 2024
View Complete Issue         Table of Contents 2019 
Marstacimab (Hympavzi) for Hemophilia A and B
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Marstacimab (Hympavzi) for Hemophilia A and B
December 9, 2024 (Issue: 1717)
Marstacimab-hncq (Hympavzi – Pfizer), a tissue factor pathway inhibitor (TFPI) antagonist, has been approved by the FDA for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients ≥12 years old who have...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Marstacimab (Hympavzi) for Hemophilia A and B
Article code: 1717b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.